Amplia Therapeutics Limited Stock Price To Earnings To Growth
| INNMF Stock | USD 0.06 0 7.41% |
Amplia Therapeutics Limited fundamentals help investors to digest information that contributes to Amplia Therapeutics' financial success or failures. It also enables traders to predict the movement of Amplia Pink Sheet. The fundamental analysis module provides a way to measure Amplia Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amplia Therapeutics pink sheet.
Amplia |
Amplia Therapeutics Limited Company Price To Earnings To Growth Analysis
Amplia Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Amplia Therapeutics Limited has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Amplia Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amplia Therapeutics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Amplia Therapeutics could also be used in its relative valuation, which is a method of valuing Amplia Therapeutics by comparing valuation metrics of similar companies.Amplia Therapeutics is currently under evaluation in price to earnings to growth category among its peers.
Amplia Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.75) % | |||
| Operating Margin | (1.75) % | |||
| Current Valuation | 4.82 M | |||
| Shares Outstanding | 194.01 M | |||
| Shares Owned By Insiders | 22.09 % | |||
| Shares Owned By Institutions | 23.14 % | |||
| Price To Earning | (1.12) X | |||
| Price To Book | 0.60 X | |||
| Price To Sales | 3.97 X | |||
| Revenue | 2.99 M | |||
| Gross Profit | 1.83 M | |||
| EBITDA | (3.64 M) | |||
| Net Income | (3.64 M) | |||
| Cash And Equivalents | 14.61 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 2.1 M | |||
| Debt To Equity | 0.1 % | |||
| Current Ratio | 31.18 X | |||
| Book Value Per Share | 0.1 X | |||
| Cash Flow From Operations | (4.4 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 25 | |||
| Beta | 0.4 | |||
| Market Capitalization | 12.13 M | |||
| Total Asset | 24.48 M | |||
| Retained Earnings | (113 M) | |||
| Working Capital | 8 M | |||
| Current Asset | 9 M | |||
| Current Liabilities | 1000 K | |||
| Z Score | -2.6 | |||
| Net Asset | 24.48 M |
About Amplia Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amplia Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amplia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amplia Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Amplia Pink Sheet
Amplia Therapeutics financial ratios help investors to determine whether Amplia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amplia with respect to the benefits of owning Amplia Therapeutics security.